Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study

Abstract

Objective:To assess the impact of Doxazosin Oral Intake Therapy on urinary symptoms and pain in patients with indwelling ureteral stentsPatients and Methods:A total of 239 patients with ureteral stone-related hydronephrosis who underwent a double-J stent insertion after ureteroscopic lithotripsy were enrolled. Patients were randomized to receive doxazosin cotrolled release 4 mg once daily for 4 weeks or matching placebo. Patients completed the brief-form Chinese version Ureteric Stent Symptom Questionnaire (USSQ) and quality of life (QoL) score 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal. The analgesic use was also recorded during the stenting period.Results:Patients in Doxazosin Oral Intake Therapy group, in the first 2 weeks and second 2 weeks with the stent in situ, expressed significant lower daytime frequency (p=0.028 and p=0.038), nocturia (p=0.021 and p=0.008) and urgency (p=0.012 and p=0.014), respectively. Similarly, flank pain score, QoL score and analgesic use were also significant less in the stenting period. There was no significant difference in scores of urinary symptoms, pain and QoL during the post-stent period between two cohorts.Conclusions:Doxazosin Oral Intake Therapy reduced stent-related urinary symptoms, pain and the negative impact on QoL.

Effect of highly concentrated hyaluronic acid/chondroitin sulphate instillation on ureteric stent‐induced discomfort after ureteroscopic lithotripsy: a multicentre randomised controlled pilot study

“…They found that the bladder mucosa normalised after the instillation. Table 4 provides a summary of existing studies about this issue, and most of the studies used the USSQ to measure the clinical discomfort caused by ureteric stenting [31][32][33][34][35][36][37][38][39][40][41]. As shown in Table 3, current existing evidence supports the specific treatment strategy to control discomfort due to ureteric stent indwelling either by a-blockers or other treatments.…”

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

“…influence on SRS in all domains. [7][8][9][10][11][13][14][15] Four of the studies refer to the effect of alfuzosin, 3 studies refer to the effect of terazosin, and 1 study refers to the effect of doxazosin. Two studies claim that patients receiving alfuzosin had lower urinary scores on the Ureteral Stent Symptom Questionnaire (USSQ) and experienced lower pain levels, 7,8 whereas the 3rd study indicates that alfuzosin has a positive effect on urinary symptoms, as depicted by the International Prostate Symptom Score (IPSS), and pain, as measured by visual analog scale (VAS), as well as diminished bladder inflammation, which was measured by the excretion of urinary glycosaminoglycans (GAG).…”

Editorial Comment: The effects of pregabalin, solifenacin and their combination therapy on ureteral double-J stent-related symptoms: A randomized controlled clinical trial

“…Therefore, smaller diameter stents should be preferred (8,9). Stent-related symptoms may be significantly mitigated with drug monotherapy or combination of beta-3 adrenergic receptor agonist, alpha-blockers and anticholinergic (10)(11)(12)(13)(14)(15)(16).…”